0.8300 -0.01 (-0.94%)
After hours: 7:42PM EDT
|Bid||0.8300 x 800|
|Ask||0.8600 x 1200|
|Day's Range||0.7920 - 0.8890|
|52 Week Range||0.6400 - 2.2200|
|Beta (5Y Monthly)||2.64|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Matinas BioPharma incurred a loss of $0.03 per share in 4Q, which met analysts’ expectations. The reported loss by the biopharmaceutical company was smaller than the prior-year quarter’s loss of $0.04 per share. Matinas’ (MTNB) research and development expenses increased 2.9% on a year-over-year basis to $3.5 million in the quarter, while total general and administrative expenses surged 30.4% to $3 million. Matinas CEO Jerome D. Jabbour said, “The completion of the head-to-head ENHANCE-IT trial of LYPDISO vs. Vascepa and the results which support the potential for LYPDISO to demonstrate a superior cardioprotective effect to Vascepa, have positioned us to identify and potentially secure a global partner for the continued development of this promising, next-generation drug.” (See Matinas stock analysis on TipRanks) On Feb. 1, Maxim Group analyst Jason McCarthy maintained a Buy rating and a price target of $3 (168% upside potential). According to McCarthy, “the overall data set for ENHANCE is actually quite good and the next step is likely an outcomes trial, potentially with a partner.” Furthermore, the analyst said, “In addition, while we await next steps for Lypdiso, don’t forget Matinas has a pipeline with updates expected in 2021 (MAT2203, MAT2501, LNC-based collaborations) and the company has cash runway likely through 2022, ~$60M. Combined, we view MTNB shares as oversold and would Buy on the weakness.” Shares have rallied 60% over the past year, while Wall Street analysts are still bullish about the stock. The Strong Buy consensus rating boasts 4 unanimous Buy ratings. Looking ahead, the average analyst price target stands at $3.67, putting the upside potential at about 227.7% over the next 12 months. Related News: KBR Provides Long-Term Financial Targets; Shares Pop 13% Bioventus’ 4Q Results Outperform Analysts’ Expectations Satsuma Posts Wider-Than-Feared Quarterly Loss More recent articles from Smarter Analyst: Tencent To Buy Back $1B In Stock; Shares Gain Pre-Market Johnson & Johnson Signs Single-Shot COVID-19 Vaccine Deal With AVAT Accenture To Snap Up Cygni In Cloud Push Chipotle Invests In Nuro In Autonomous Delivery Push
Matinas BioPharma Hldgs (AMEX:MTNB) unveils its next round of earnings this Monday, March 29. Get prepared with Benzinga's ultimate preview for Matinas BioPharma Hldgs's Q4 earnings. What Are Earnings, Net Income, And Earnings Per Share? Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding. Earnings And Revenue Wall Street analysts see Matinas BioPharma Hldgs reporting a quarterly loss of $0.03 per share on sales of $1.02 million. Matinas BioPharma Hldgs EPS in the same period a year ago totaled $0.04. Revenue was $0.00. What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin. View more earnings on MTNB If the company were to match the consensus estimate, earnings would be up 25.0%. Revenue would be unchanged from the year-ago period. The company's reported EPS has stacked up against analyst estimates in the past like this: Quarter Q3 2020 Q2 2020 Q1 2020 Q4 2020 EPS Estimate -0.03 -0.03 -0.03 -0.03 EPS Actual -0.03 -0.03 -0.03 -0.04 Revenue Estimate 20.00 K 20.00 K 30.00 K 20.00 K Revenue Actual 95.83 K 0 0 0 Stock Performance Shares of Matinas BioPharma Hldgs were trading at $1.1 as of March 25. Over the last 52-week period, shares are up 57.12%. Given that these returns are generally positive, long-term shareholders are probably content going into this earnings release. Do not be surprised to see the stock move on comments made during its conference call. Matinas BioPharma Hldgs is scheduled to hold the call at 08:00:00 ET and can be accessed here. See more from BenzingaClick here for options trades from BenzingaUnderstanding Bank of Commerce's Ex-Dividend DateUnderstanding Enerplus Ex-Dividend Date© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.